ZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIO

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Zenas BioPharma, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Investigation Details - The investigation is focused on Zenas BioPharma, Inc. (NASDAQ: ZBIO) regarding possible misleading information that may have affected investors [1]. - Shareholders who purchased Zenas BioPharma securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket fees or costs [2]. Group 2: Class Action Information - Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Zenas BioPharma [2]. - Interested investors can join the prospective class action by submitting a form or contacting the firm directly [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3].